Format

Send to

Choose Destination
Psychiatry J. 2015;2015:352979. doi: 10.1155/2015/352979. Epub 2015 Aug 19.

Near-Infrared Transcranial Radiation for Major Depressive Disorder: Proof of Concept Study.

Author information

1
Depression Clinical & Research Program, Massachusetts General Hospital, Boston, MA 02114, USA.
2
Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA.
3
LiteCure LLC, Newark, DE 19702, USA.
4
Depression Clinical & Research Program, Massachusetts General Hospital, Boston, MA 02114, USA ; Department of Psychiatry, The Mount Sinai Hospital, New York, NY 10029, USA.

Abstract

Transcranial near-infrared radiation (NIR) is an innovative treatment for major depressive disorder (MDD), but clinical evidence for its efficacy is limited. Our objective was to investigate the tolerability and efficacy of NIR in patients with MDD. We conducted a proof of concept, prospective, double-blind, randomized study of 6 sessions of NIR versus sham treatment for patients with MDD, using a crossover design. Four patients with MDD with mean age 47 ± 14 (SD) years (1 woman and 3 men) were exposed to irradiance of 700 mW/cm(2) and a fluence of 84 J/cm(2) for a total NIR energy of 2.40 kJ delivered per session for 6 sessions. Baseline mean HAM-D17 scores decreased from 19.8 ± 4.4 (SD) to 13 ± 5.35 (SD) after treatment (t = 7.905; df = 3; P = 0.004). Patients tolerated the treatment well without any serious adverse events. These findings confirm and extend the preliminary data on NIR as a novel intervention for patients with MDD, but further clinical trials are needed to better understand the efficacy of this new treatment. This trial is registered with ClinicalTrials.gov NCT01538199.

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center